Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GLMD | US
-0.04
-6.77%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.62
0.66
0.68
0.62
Galmed Pharmaceuticals Ltd. a biopharmaceutical company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol an oral therapy which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition it engages in the development of Amilo-5MER a 5 amino acid synthetic peptide methionine threonine alanine aspartic acid and valine. It has a license agreement with Samil Pharma. Co. Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv Israel.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
100.7%1 month
88.9%3 months
81.4%6 months
80.7%-
-
0.44
-
-
0.32
-
-
-6.14M
927.25K
927.25K
-
-
-
-
-52.67
-
2.30
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.19
Range1M
0.20
Range3M
0.71
Rel. volume
0.34
Price X volume
11.58K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Evofem Biosciences Inc | EVFM | Biotechnology | 0.009 | 902.96K | 1.12% | 0.00 | 0.00% |
| Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 0.2 | 868.39K | -6.76% | n/a | 4.18% |
| Pasithea Therapeutics Corp. Common Stock | KTTA | Biotechnology | 0.8 | 835.93K | 0.44% | n/a | 0.00% |
| Biodexa Pharmaceticals | BDRX | Biotechnology | 0.95 | 551.80K | 4.86% | n/a | 0.00% |
| VINC | VINC | Biotechnology | 0.0126 | 389.10K | n/a | 12.51% | |
| Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.0005 | 259.17K | -50.00% | n/a | 20.48% |
| ZVSA | ZVSA | Biotechnology | 0.2301 | 247.17K | -11.50% | 0.00 | 0.00% |
| Windtree Therapeutics Inc | WINT | Biotechnology | 0.01 | 36.80K | -25.93% | n/a | 36.99% |
| Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0.0001 | 12.68K | n/a | 113.12% | |
| Syros Pharmaceuticals Inc | SYRS | Biotechnology | 0.0002 | 5.36K | 0.00% | n/a | -954.99% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.32 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.44 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 81.38 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 927.25K | 3.66B | Emerging |